### 7.9.3 CSU - Message Reporting Monthly Patient Data Updates to the Sponsor

MSH|^~\&|PDMS|MDACC|CTMS|NCI|200006050927||CSU^C09^CRM_C09|...&lt;cr>

PID|1||235925||J^F^M||19350616|...&lt;cr> [note:anonymous]

CSR|T93-080^NCI|ID93-030^^MDACC|MDACC|14||19941205|...&lt;cr>

CSS|^Prestudy|19941204|C^compliant^NCI&lt;cr>

OBR|1|1234|1234|3^EligibilChecklist^StudyFormsList|||19941205|...&lt;cr>

**Note: The clinical trials section probably needs its own definition of OBR. OBR-2&3 have condition rules indicating that the placer and filler numbers must be present in either the ORC or the OBR. Since an ORC is not present, then these fields must be populated in the OBR. My guess is that clinical trials arenâ€™t interested in the placer and filler number.**

OBX|1|CWE|ELIG1^Elig Crit 1^NCI|Text Elig Crit 1|Y|...&lt;cr>

OBX|2|CWE|ELIG2^Elig Crit 2^NCI||Y|...&lt;cr>

OBR|2|1235|1235|4^Prestudy Form^StudyFormsList|||19941205|...&lt;cr>

OBX|1|CWE|QOL^Quality of Life^NCI||2\T\3\T\2\T\4\T\2^SPITZER|...&lt;cr>

OBX|2|CWE|PRICHEM^Prior Chemo^NCI||Yes|...&lt;cr>

OBX|3|CWE|PRIBIOL^Prior Biologics^NCI||No|...&lt;cr>

OBX|4|NM|NUMREM^Number Prior Remissions^NCI||2|...&lt;cr>

OBR|3|932^OE|243789^LAB|88304^SURG PATH REPORT|||19940101|...&lt;cr>

OBX|1|CWE|88304&ANT|1|9999^PANCREAS^SNM|...&lt;cr>

OBX|2|CWE|88304&IMP|2|9999^ADENOCARCINOMA^SNM|...&lt;cr>

OBR|4|933^OE|243790^LAB|85022^CBC|||199412050800|...&lt;cr>

OBX|1|NM|718-7^HEMOGLOBIN:^LN||13.4|GM/DL|14-18|N||S|F|19860522|...&lt;cr>

> [cbc values]

OBX|2|NM|4544-3^HEMATOCRIT:^LN||40.3|%|42-52|L||S|F|19860522|...&lt;cr>

OBX|3|NM|789-8^ERYTHROCYTES:^LN||4.56|10*6/ml|4.7-6.1|L||S|F|19860522|...&lt;cr>

OBX|4|NM|787-22^ERYTHROCYTE MEAN CORPUSCULAR VOLUME:^LN||88|fl |80-94|N||S|F|19860522|...&lt;cr>

OBX|5|NM|785-6^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN:^LN||29.5|pg |27-31|N||N|F|19860522|...&lt;cr>

OBX|6|NM|786-4^ERYTHROCYTE MEAN CORPUSCULAR HEMOGLOBIN CONCENTRATION:^LN||33|%|33-37|N||N|F|19860522|...&lt;cr>

OBX|7|NM|6690-2^LEUKOCYTES:^LN||10.7|10*3/ml|4.8-10.8|N||N|F|19860522|...&lt;cr>

OBX|8|NM|764-1^NEUTROPHILS BAND FORM/100 LEUKOCYTES:^LN||2|%|||||F|...&lt;cr>

OBX|9|NM|769-0^NEUTROPHILS SEGMENTED/100 LEUKOCYTES:^LN||67|%|||||F |...&lt;cr>

OBX|10|NM|736-9^LYMPHOCYTES/100 LEUKOCYTES:^LN||29|%|||||F|...&lt;cr>

OBX|11|NM|5905-5^MONOCYTES/100 LEUKOCYTES:^LN||1|%|||||F|...&lt;cr>

OBX|12|NM|713-8^EOSINOPHILS/100 LEUKOCYTES:^LN||2|%|||||F|...&lt;cr>

OBR|5|934^OE|243791^LAB|80004^ELECTROLYTES|||199412050800|...&lt;cr>

OBX|1|NM|2947-0^SODIUM:^LN||150|mmol/l|136-148|H||A|F|19850301 |...&lt;cr>

OBX|2|NM|2823-3^POTASSIUM:^LN||4.5|mmol/l|3.5-5|N||N|F|19850301|...&lt;cr>

> [electrolytes values]

OBX|3|NM|2069-3^CHLORIDE:^LN||102|mmol/l|94-105|N||N|F|19850301|...&lt;cr>

OBX|4|NM|2028-9^CARBON DIOXIDE.TOTAL:^LN||27|mmol/l|24-31|N||N|F |19850301|...&lt;cr>

CSP|^Course 1|19941205|19950120|Y^Toxicity and Response^NCI |...&lt;cr>

CSS|^Course Completion|19950120|...&lt;cr>

OBR|1|935^OE|243791^LAB|2039-6^CARCINOEMBRYONIC AG:^LN|||19941008|...&lt;cr>

OBX|1|NM|2039-6^CARCINOEMBRYONIC AG:^LN||15.2|IU |...&lt;cr>

OBR|2|1236|1236|10^Course Completion Form^StudyPhaseFormsList|||19950120 |...&lt;cr>

OBX|1|CWE|CRSRESP^Course Response^NCI||4^Partial Response|...&lt;cr>

OBX|2|NM|DRUGDISP^Capsules Dispensed^NCI||60|...&lt;cr>

OBX|3|NM|DRUGRETN^Capsules Returned^NCI||5|...&lt;cr>

OBX|4|ID|DXCOMP^Diagnostic Tests Compliance^NCI||Y|...&lt;cr>

OBX|5|CWE|PERSTAT^Performance Status^NCI||3^ZUBRODS|...&lt;cr>

OBR|3|1237|1237|9999^Adverse Events|...&lt;cr>

OBX|1|CWE|9999&EVENT|1|45^Vomiting^NCI|...&lt;cr>

OBX|2|DT|9999&ONSET|1|19941215|...&lt;cr>

OBX|3|DT|9999&RESOLUTION|1|19941217|...&lt;cr>

OBX|4|CWE|9999&GRADE|1|M^MODERATE|...&lt;cr>

OBX|5|CWE|9999&RELATION_TO_RX|1|L^LIKELY|...&lt;cr>

OBX|6|CWE|9999&EVENT|2|303^Dyspnea^NCI|...&lt;cr>

OBX|7|DT|9999&ONSET|2|19941231|...&lt;cr>

OBX|8|DT|9999&RESOLUTION|2|...&lt;cr>

OBX|9|CWE|9999&GRADE|2|MI^MILD|...&lt;cr>

OBX|10|CWE|9999&RELATION_TO_RX|2|U^UNLIKELY|...&lt;cr>

[Note: Needs to maintain compatibility with ongoing product experience message efforts.]

[Note2: There are other possible OBX suffixes defined by FDA: APEX/ NADIR, ACTION, THERAPY, OUTCOME, RECHALLENGE.]
